
Company that develops novel osteoarthritis treatment raises capital with Sciety
NEW COMPANY AT SCIETY. Osteoarthritis affects more than 320 million people globally and is a leading source of chronic pain and disability in Europe and the US. Only half of the patients receive adequate pain relief. Sciety is now financing a company whose drug candidate has the potential to provide




